glimepiride has been researched along with empagliflozin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Broedl, UC; Kim, G; Ridderstråle, M; Svaerd, R; Woerle, HJ; Zeller, C | 1 |
| Andersen, KR; Broedl, UC; Kim, G; Ridderstråle, M; Woerle, HJ; Zeller, C | 1 |
| Chirila, C; Davenport, E; Hach, T; Kaschinski, D; Palencia, R; Pfarr, E; Zheng, Q | 1 |
| Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A | 1 |
| Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y | 1 |
| Kaspers, S; Kohler, S; Salsali, A; Woerle, HJ; Zeller, C | 1 |
| Andersen, KR; Ridderstråle, M; Rosenstock, J; Salsali, A; Woerle, HJ | 1 |
| Alexander, GC; Heyward, J; Mansour, O; Olson, L; Singh, S | 1 |
| Lamotte, M; Men, P; Ramos, M; Salem, A; Ustyugova, A; Zhang, YJ | 1 |
| Hasebe, M; Ito, K; Kondo, Y; Satoh, S; Tamura, H; Terauchi, Y | 1 |
| Andreozzi, F; Cascini, GL; Cicone, F; Fiorentino, TV; Miceli, S; Papa, A; Sciacqua, A; Sesti, G; Succurro, E; Veltri, P; Vizza, P | 1 |
| Bhat, MH; Masoodi, SR; Mir, SA; Najar, IA; Patyar, RR; Patyar, S | 1 |
| Abbas, SQ; Ahmad, SA; Ahmed, S; Ahmed, Z; Akhter, E; Andleeb, S; Asif, M; Hussain, MW; Iqbal, A; Ishaqui, AA; Jawed, B | 1 |
2 review(s) available for glimepiride and empagliflozin
| Article | Year |
|---|---|
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride.
Topics: Adult; Aged; Benzhydryl Compounds; Bone Density; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Randomized Controlled Trials as Topic; Sulfonylurea Compounds | 2018 |
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis.
Topics: Amputation, Surgical; Benzhydryl Compounds; Glucosides; Humans; Lower Extremity; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Risk; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2020 |
6 trial(s) available for glimepiride and empagliflozin
| Article | Year |
|---|---|
Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Topics: Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Body Mass Index; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2013 |
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome | 2014 |
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds | 2016 |
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2018 |
Comparison of the effects of empagliflozin and glimepiride on endothelial function in patients with type 2 diabetes: A randomized controlled study.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Endothelium; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fluorodeoxyglucose F18; Glucose; Humans; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
5 other study(ies) available for glimepiride and empagliflozin
| Article | Year |
|---|---|
Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride.
Topics: Adult; Benzhydryl Compounds; Clinical Protocols; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Personal Satisfaction; Quality of Life; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Incidence; Kidney; Kidney Diseases; Male; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2017 |
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China.
Topics: Benzhydryl Compounds; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sulfonylurea Compounds; Treatment Outcome | 2021 |
Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; India; Metformin; Prospective Studies; Quality of Life | 2022 |
Assessment of empagliflozin add-on therapy to metformin and glimepiride in patients with inadequately controlled type-2 diabetes mellitus.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Follow-Up Studies; Glycated Hemoglobin; Humans; Metformin | 2022 |